INTRODUCTION
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) was fi rst isolated from the white hellebore by Takaoka in 1940 and then isolated from Polygonum cuspidatum (Japanese knot-weed) in 1963 by Nonomura. [1] Resveratrol, a phytoalexin found in over 300 edible plants, including grapes, berries, and peanuts, is produced by plants as a defense mechanism against microbial injury, fungal infection or environmental stress. [2] It also found in red wine (0.1-15 mg/l), which proves, in part, the "French paradox" (the comparatively low incidence of cardiovascular disease in the French population despite regular consumption of a high-fat diet [HFD] ), and may be responsible
MATERIALS AND METHODS
We searched "PubMed," "Scopuse," and "Google Scholar" and used the following keywords: "Liver," "hepatic" and "resveratrol" [ Figure 1 ]. Studies should be in English. Both in vivo and in vitro studies were included. No time limiting considered for this search. So, among 321 articles fi nally 76 articles were selected for this review. Study diagram is as follow:
In human liver myofi broblasts trans-resveratrol markedly reduced proliferation of myofi broblasts in a dose-dependent manner and deactivated human liver myofi broblasts. [13] It also inhibited platelet-derived growth factor signaling via receptor inactivation, whereas it reduced epidermal growth factor-dependent DNA synthesis via inhibition of the phosphatidylinositol 3-kinase/Akt pathway, possibly through inactivity of phospho-inositidedependent kinase-1. [14] Resveratrol inhibited HepG2 cellular triacylglycerol (TG) accumulation (which were incubated with high concentration of glucose and insulin) via activating AMP-activated protein kinase (AMPK) and downregulating sterol regulatory element binding protein 1c and fa y acid synthase gene expressions. [15] Nah et al. [16] showed that resveratrol eff ectively protects HepG2 cells from ethanol and hydrogen peroxide oxidative stress. Reduction in intracellular glutathione (GSH) depletion, cell proliferation, mitotic Cdk, malondialdehyde (MDA), reactive oxygen species (ROS) production, apoptosis, and cell death was also reported. Resveratrol amplifi es the profi brogenic activation of human hepatic LX-2 stellate cells, [11] increases apoptosis and inhibits cell growth in hepatic stellate cells. [17] Resveratrol pretreatment eff ectively protected hepatocytes from oxidative stress, [18, 19] increasing the activities of catalase (CAT), superoxide dismutase (SOD), GSH peroxidase (GPx), NADPH quinone oxidoreductase, and GSH-S-transferase. [18] Resveratrol also protected the cells against hydroquinone-induced toxicity through its antioxidant function and possibly a suppressive eff ect on the expression of cytochrome P450 2E1. [20] Relatively higher concentrations of resveratrol (≥1 mM) inhibited apoptosis of the mouse primary hepatocytes and increased cell viability in a dose-dependent manner, and in particular the survival rate of the hepatocytes was recovered from 28% to near 100% by 5 mM resveratrol. [20] In isolated hepatocytes from normal rats a resveratrol-induced short-term inhibition of fa y acids (specially formation of palmitic acid) and TG synthesis occurred. [21] Cerny et al. [22] have evaluated the eff ects of resveratrol as compared to silymarin pretreatments on tert-butylhydroperoxide (tBH) induced apoptotic/necrotic markers in hepatocytes. They found that resveratrol reduced hepatocyte necrotic and apoptotic eff ects caused by tBH and suggested that resveratrol has signifi cant protective ability against tBH-induced oxidative damage. 10 μM resveratrol showed the similar eff ect of 500 μM silymarin. The authors concluded that resveratrol may play a chemopreventive role through antiapoptotic and antinecrotic eff ects via reducing nitric oxide synthase 2 (NOS-2) and hemoxygenase-1 in tBHinduced hepatocyte intoxication. [22] Eff ects of antioxidants, resveratrol, quercetin, and N-acetylcysteine on the functions of cultured rat hepatic stellate cells and Kupff er cells have been studied; resveratrol could have therapeutic potential against liver injury by regulating functions of hepatic stellate cells and Kupffer cells. [10] Resveratrol also had 
RESULTS
Several in vivo and in vitro studies provide evidence for the potential role of resveratrol as a hepatoprotective agent. The protective eff ects of resveratrol have been elucidated in animal and in both parenchymal (hepatocyte) as well as nonparenchymal liver cells such as stellate cells and Kupff er cells.
These studies are summarized in Table 1 (in vitro studies) and Table 2 (in vivo studies).
In vitro studies
Several in vitro studies [ Table 1 ] have shown the hepatoprotective eff ects of resveratrol in diff erent cell cultures. [13] Human liver myofi broblasts
Resveratrol inhibits platelet-derived growth factor signaling ↓receptor activation of plateletderived growth factor signaling Godichaud et al. [14] Cultured human HepG2 hepatocytes [11] HSCs Resveratrol inhibits cell growth ↓cell growth, ↑S-phase cell cycle arrest, ↑apoptosis 100 nM or 1 μM Souza et al. [17] Primary rat hepatocytes Resveratrol could be a useful drug for the protection of liver cells from oxidative stress induced damage ↑activities of (CAT, SOD, GSH peroxidase, NADPH quinone oxidoreductase and GSH-S-transferase) 25, 50 and 75 μM Rubiolo et al. [18] Primary rat hepatocytes Resveratrol protects primary rat hepatocytes from oxidative stress induced cell death ↓necrosis, ↓ROS 25, 50 or 75 μM Rubiolo and Vega [19] Mouse primary hepatocytes
Resveratrol protected the cells against hydroquinone-induced toxicity ↓apoptosis, ↑cell viability, ↓hydroquinone-induced expression of cytochrome P450 2E1 mRNA 0.5 or 1 or 5 mM Wang et al. [20] Rat hepatocyte Resveratrol has hypolipidemic effect ↓total fatty acid, ↓formation of palmitic acid formation, ↓ACC d activity, ↓TGs 0-100 μM Gnoni and Paglialonga [21] Rat [10] Hepatoma G2 cells Pretreatment with resveratrol blocked the apoptotic biochemical events ↓CTN i -induced cell apoptosis and oxidative stress, ↓ROS, ↓CTN-induced activation of caspases-3,-9, and PAK2 j 5, 10, 20, 30, 40 μM
Chen and Chan [23] Human hepatocytederived cancer cell line HepG2
Resveratrol inhibits the proliferation of HepG2 cells ↓cell proliferation, ↓ROS, ↑apoptosis, ↑iNOS and eNOS expression, ↑NOS activity, ↑NO production 10 −7 M Notas et al. [24] HepG2 [25] Human SK-HEP-1 hepatic cancer cells
Resveratrol causes hepatic cancer cell death ↓expression of antioxidant proteins, ↓ROS
μM
Choi et al. [26] HepG2 HCC cells PYB, trans-3,40-dihydroxy-20,30,5 trimethoxystilbene was more effective in inhibiting the growth of HepG2 HCC cells than resveratrol PYB could inhibit the invasion of HCC cells 50 μM Wang et al. [3] Liver of Wistar rats Resveratrol plus ethanol counteract the ethanol-induced impairment of energy metabolism protective eff ects in carcinoma HepG2 cells. Pretreatment with resveratrol in these cells blocked the apoptotic biochemical events. [23] It also inhibited the proliferation of HepG2 cells. [24, 25] Resveratrol causes hepatic cancer cell death by suppressing the expression of antioxidant proteins and reduction of ROS. [26] Wang et al. compared the eff ects of phoyunbene B (PYB) and resveratrol; they found that PYB, trans-3,40-dihydroxy-20,30,5 trimethoxystilbene) was more eff ective in inhibiting the growth of HepG2 hepatocellular carcinoma cells than resveratrol. [3] Resveratrol can also counteract the ethanol-induced impairment of energy metabolism by maintaining ATP content and increasing mitochondrial ATP turnover. [27] In vivo studies [ Table 2 ] Liver transplantation To study the eff ect of resveratrol on transplantation Wu et al. used Sprague-Dawley rats as donors and Wistar rats as recipients then 25, 50, and 100 mg/kg resveratrol was given once a day to the recipient mice. Increase in survival period and decrease in severity of rejection was seen in a larger dose of resveratrol as compared to the others. [28] Another study also reported an increase in survival period, decrease in the expression of protein kinase CѲ, ↓IкB kinase-β protein in lymphocytes. [29] Combination use of resveratrol (100 mg/Kg) and cyclosporine (20 mg/Kg) had be er outcomes than cyclosporine alone. [30] This combination increased survival period and albumin and decreased serum total bile acid, alanine aminotransferase (ALT), serum interleukin-2 (IL-2) and interferon-γ (INF-γ) levels, activation of transcription factor nuclear factor-κB (NF-kB) peripheral blood T-lymphocytes and the severity of rejection. Resveratrol alone (100 mg/Kg) was able to increase survival period and albumin, and decrease serum total bile acid, ALT, IL-2, INF-γ, activation of transcription factor NF-κB and severity of rejection. [31] Cancer and metastasis Resveratrol could inhibit the growth of murine hepatoma 22, a er the mice bearing H22 tumor were treated with 10 mg/kg or 15 mg/kg resveratrol for 10 days. [32] It also induced the S phase arrest of H22 cells and enhanced the antitumor eff ect of 5-FU on murine hepatoma 22. [32] Yu et al. [33] used murine transplanted hepatoma H22 model to evaluate the in vivo antitumor activity of resveratrol and reported that resveratrol exhibits anti-tumor activities on murine hepatoma H22. The underlying anti-tumor mechanism of resveratrol might involve the inhibition of the cell cycle progression by decreasing the expression of cyclin B1 and p34cdc2 protein. [33] Bishayee et al. [34] have examined the underlying mechanisms of resveratrol chemoprevention of hepatocarcinogenesis by investigating the effects of resveratrol on oxidative damage and infl ammatory markers during diethylnitrosamine (DENA)-initiated rat liver carcinogenesis. In this study, resveratrol elevated the protein and mRNA expression of hepatic NF E2-related factor 2 (Nrf2). Resveratrol also reduced the hepatic iNOS protein expression and thiobarbituric acid reactive substances (TBARS) in these animals. It has been shown that resveratrol (50, 100 and 300 mg/kg) inhibits DENA-induced hepatocyte nodules in Sprague-Dawley rats in a dose-responsive manner. [35] Resveratrol exerts chemoprevention of hepatocarcinogenesis possibly through anti-infl ammatory eff ects during DENA-evoked rat liver carcinogenesis by suppressing elevated levels of heat shock protein (HSP)70, COX-2 as well as NF-кB. [35] DENA-initiated hepatocarcinogenesis was suppressed by resveratrol administration for 20 weeks. [36] Resveratrol treatment reversed the DENA-induced alteration of the level and expression of hepatic tumor necrosis factor-alpha (TNF-α) and IL-1β and IL-6. [36] Luther et al. [2] also showed that long-term dietary administration of resveratrol dose-dependently suppressed hepatic tumor multiplicity.
Another study [37] investigated anti-infl ammatory properties of resveratrol and reported that 1 mg/Kg resveratrol remarkably inhibited hepatic retention and metastatic growth of melanoma cells by 50% and 75%, respectively. The mechanism involved IL-18 blockade at three levels: First, resveratrol prevented IL-18 augmentation in the blood of melanoma cell-infi ltrated livers. Second, resveratrol inhibited IL-18-dependent expression of VCAM-1 by tumoractivated hepatic sinusoidal endothelium, preventing melanoma cell adhesion to the microvasculature. Third, resveratrol inhibited adhesion and proliferation-stimulating eff ects of IL-18 on metastatic melanoma.
Hepatic glucose metabolism
Burgess et al. [38] studied the eff ect of resveratrol (100 mg/kg) on glucose metabolism in a Swine Model of Metabolic Syndrome induced by hypercholesterolemic diet. Increase in insulin receptor substrate 1, phosphorylated AKT, glucose transporter type 4 (Glut 4), peroxisome proliferating activation receptor-γ coactivator 1α, peroxisome proliferatoractivated receptor-α, peroxisome proliferator-activated receptor-γ, phosphorylated AKT at threonine 308 expression and reduction in retinol binding protein 4 was seen according to resveratrol consumption.
Hepatic ischemia
Liver ischemia-reperfusion (I/R) injury occurs in many clinical conditions, including liver surgery and transplantation. Oxygen free radicals generated during I/R reduce endogenous antioxidant systems and contribute to hepatic injury. As resveratrol has antioxidant properties, diff erent studies have conducted to examine the possible eff ect of resveratrol. [28] Sprague-Dawley rats as donors/Wistar rats as recipients ↑survival period, ↑longivity Wu et al. [29] Sprague-Dawley rats as donors and Wistar rats as recipients
Wu et al. [30] Sprague-Dawley rats as donors and Wistar rats as recipients ↑survival period ↑albumin, ↓serum total bile acid, Wu et al. [32] Balb/c mice 10 days Induce the S phase arrest of H22 cells and enhance the anti-tumor effect of 5-FU on murine hepatoma 22
Yu et al. [33] H22 tumour bearing mice 10 days Anti-tumour activities, ↓expression of cyclinB1 and p34cdc2 protein.
Blocking of S stage of tumour cells
Bishayee et al. [34] Sprague-Dawley rats 20 weeks
Bishayee et al. [35] Sprague-Dawley rats 50, 100 or 300 mg/kg 24 weeks
Mbimba et al. [36] Sprague-Dawley rats 50, 100 and 300 mg/kg 20 weeks
Luther et al. [2] Sprague-Dawley rats 50, 100 or 300 mg/kg 18 weeks ↓hepatic tumor multiplicity Salado et al. [37] C57BL/6J mice 1 mg/kg 12 days ↓metastatic growth of melanoma, ↓IL-18, ↓expression of VCAM-1
Hepatic glucose metabolism
Burgess et al. [38] Pigs/3 groups, control/ hypercholesterolemic diet (HCC)/hypercholesterolemic diet with supplemental resveratrol (HCRV) 100 mg/kg 11 weeks ↑insulin receptor substrate 1, [40] Sprague-Dawley rats 0.02 or 20 mg/kg ↓ALT, ↓AST, ↑Cu/Zn-SOD and CAT Activities, ↑GSH, ↑GSH reductase, ↑Cu/Zn-SOD, and ↑ CAT activities Plin et al. [41] Wistar rats ↓lipid peroxidation, protects mitochondrial functions, ↑respiratory chain activity, ↓activation of the cellular markers of necrosis and apoptosis Hepatic Chemical injury Rivera et al. [42] Wistar rats 10 mg/kg ↓GSH, ↓GSH/GSSG ratio were decreased by CCl 4 ; both effects were completely prevented by any of the compounds tested ↓lipid peroxidation, ↓activity of γ-glutamyl transpeptidase,
↓ALT
Fan et al. [43] Swiss albino mice 30 mg/kg Single dose ↓AST, ↓ALT, ↓SALP, LDH, ↓γ-GT and ↓CK, ↓total bilirubin, ↓urea and ↓uric acid, ↓hepatic peroxidative stress,
↑GSH, ↓GSSG
Lodovici et al. [44] Fisher 344 rats 50 mg/kg 14 days
↑GSH/GSSG
Tunali-Akbay et al. [45] Wistar albino rats 20 mg/kg 5 days ↓hepatic MDA, ↓ALT, ↓AST, ↓TNF-α, ↓LDH, ↑liver GSH Roy et al. [46] Wistar rats 100 or 200 mg/kg 8 weeks ↓TNF-α, ↓IL-6, ↓liver MDA, ↓hepatocyte nodules, ↓apoptosis Vitaglione et al. [47] Sprague-Dawley rats 3 mg/kg 14 days ↓lipid peroxidation (↓MDA) 
Duration Main result
Hepatic toxicity El-Agamy [48] Fischer rats 10 mg/kg BW 90 days No effect on afl atoxin B1-induced liver injury
Hamadi et al. [49] Sprague-Dawley rats 
Hepatic cholestatic injury
Chan et al. [50] C57BL/6 mice 4 mg/kg 3 days or 7 days ↓ALT, ↓AST, ↓TNF-a, ↓IL-6 mRNA, Yu et al. [52] Sprague-Dawley rats 30 mg/kg
Single dose ↓myeloperoxidase activity, ↓ICAM-1, ↓IL-6, ↓ALT, ↓AST
Heoatic alcohol injury
Bujanda et al. [53] Balb/c mice/four groups (control, resveratroltreated control, alcohol and resveratrol-treated alcohol) 10 mg/ml in drinking water 6 weeks ↓ALT, ↓AST, ↓IL-1, ↓severity of liver lesions, ↓mortality Kasdallah-Grissa et al. [54] Wistar rats 5 g/kg food 6 weeks ↓hepatic lipid peroxidation, ↑SOD**, ↑GPx and ↑CAT activities in the liver Jinghui and Yingbao [55] 25, 50 or 100 mg/kg 7 days ↓TNF-α, ↓IL-6, ↓ICAM-1, ↓liver NFκB p65, ↓phosphorylating IκB-α
Hepatic oxidative damage
Schirmer et al. [56] Zebrafi sh 5 or 50 mg/l 30 or 60 min ↓expression levels of the SIRT3, SIRT4, and NAMPT genes.
↑NADH levels,
Schmatz et al. [12] Streptozotocin-induced Chang et al. [57] Long-Evans rats 0.1 or 1 mg/kg 7 days ↓superoxide anion, PCL and Mn-SOD protein expression in the hepatic tissues, ↓activated form of NF-κB,
Sebai et al. [58] Wistar rats 20mg/kg 7 days ↓LPS-induced lipoperoxidation, ↑SOD, ↑CAT, ↑glutathione peroxidase (GPx) activity, ↓NO, ↓endotoxemia-induced hepatic tissue injury, ↓liver iron Rocha et al. [59] Wistar rats 1 mg/kg 30 days ↓glucose level, ↑SOD, ↓ox-LDL, ↓hepatic oxidative stress. In standardfed-rats reduced ↓GSH-antioxidant defense system and ↑hepatic lipid hydroperoxide Bagul et al. [60] Sprague-Dawley rats 10 mg/kg 8 weeks ↓blood glucose, ↓triglyceride, ↓uric acid,
↓NO, ↓TBARS
Palsamy et al. [61] Wistar rats 30 days 5 mg/kg b.w. ↓TNF-α, ↓IL-1β, ↓IL-6, ↓NF-κB, ↓liver NO, ↓lipid peroxides, ↓hydroperoxides, ↓protein carbonyls, ↑activity of (SOD, CAT, GPx, GST and GR)
Upadhyay et al. [62] Swiss albino mice 10 mg/kg 1-4 weeks ↓ALT, ↓AST, ↓lipid peroxidation Farghali et al. [63] Wistar rats 2.3 mg/kg i.p (10 lmol/ kg) Single dose ↓ALT, ↓AST, ↓α-GST, ↑CAT, ↓TBARS, ↓conjugated dienes Kirimlioglu et al. [64] Wistar albino rats 30 mg/kg 7 days ↓PH-induced lipid peroxidation, ↓hepatic GSH,
↓NO

Sengottuvelan
and Nalini [65] Wistar rats 8 mg/kg 30 weeks ↓activity of SOD, CAT, Gpx, GST and GR, ↓GSH, Vitamin C, Vitamin E levels (Contined) [68] Wistar rats 0.04% or 0.06% 4 months ↓liver weight, ↓liver fat concentration, ↓steatosis, ↓TBARS, ↓MDA Poulsen et al. [69] Wistar rats 100 mg resveratrol 8 weeks ↑hepatic uncoupling protein 2 expression Alberdi et al. [70] Sprague-Dawley rats Cho et al. [71] C57BL/6J mice 0·005 or 0·02% (w/ Shang et al. [15] Wistar rats 100 mg/kg 10 weeks ↓hepatic TG, ↓SREBP-1c, ↓FAS, ↑phosphorylation of AMPK Shiozaki et al. [74] mouse P10 (SAMP10)
↑SOD2
Zhu et al. [75] Sprague-Dawley rats Gedik et al. [39] investigated the effects of resveratrol (10 μmol/L) on the liver I/R injury in rats. Rats underwent liver ischemia for 45 min followed by reperfusion for 45 min. They reported that the activity of aminotransferase increased by resveratrol supplementation, while signifi cant decrease in MDA, hepatic injury score and histopathological changes in livers and elevation in SOD, CAT, GSH resveratrol were occured.
Another study by Hassan-Khabbar et al. [40] showed decrease in aminotransferase levels by about 40% and improvement of sinusoidal dilatation. In this study, trans-resveratrol preserved antioxidant defense by preventing total and reduced GSH depletion caused by I/R. At 0.2 mg/kg, trans-resveratrol signifi cantly increased GSH reductase, Cu/Zn-SOD, and CAT activities. However, at a high dose (20 mg/kg), trans-resveratrol became prooxidant with an aggravation of liver injury evaluated by aminotransferase release and histological analysis and associated with a depletion of total and reduced GSH levels and a decrease of antioxidant enzyme activities.
Plin et al. [41] investigated the effect of the natural phytoalexin resveratrol on the prevention of liver injuries induced by 40-h cold preservation followed by a warm reperfusion. They concluded that resveratrol inhibits lipid peroxidation and protects mitochondrial functions. It improves respiratory chain activity and prevents opening of the permeability transition pore, allowing be er recovery of ATP energetic charge. Resveratrol also limits the activation of the cellular markers of necrosis and apoptosis.
Postischemic treatment with resveratrol (0.02 and 0.2 mg/kg) resulted in a significant decrease in aminotransferase, IL-1b and IL-6 plasma levels by about 40%, 60%, and 40%, respectively, compared to the vehicle I/R group. [82] Hepatic chemical injury Rivera et al. [42] examined the effect of resveratrol and trimethylated resveratrol on hepatotoxicity induced by carbon tetrachloride (CCl 4 ). The GSH/GSSG (oxidized GSH) ratio decreased in the groups receiving CCl 4 and resveratrol associated with an increase in GSSG. In blood GSH and the GSH/GSSG ratio were decreased by CCl 4 ; both effects were completely prevented by any of the compounds tested. Lipid peroxidation and the activity of γ-glutamyl transpeptidase were increased signifi cantly a er CCl 4 . Resveratrol partially prevented these increases and surprisingly, trimethylated resveratrol completely prevented the increase of these markers. Both compounds partially but signifi cantly prevented the increase in the activity of alanine aminotransferase.
In another study, resveratrol was able to mitigate hepatic damage induced by acute intoxication of CCl 4 and showed pronounced curative eff ect against lipid peroxidation and deviated serum enzymatic variables as well as maintained GSH status toward control. [43] In a model of chemically induced acute hepatic injury, resveratrol at dose of 50 mg/kg/day administered for 14 days long could ameliorate hepatic injury by its antioxidant and scavenging properties, through a reduction of xanthine oxidase activity, a partial restoration of GSH/GSSG ratio in addition to its capacity to inhibit apoptosis. [44] To investigate the possible protective eff ect of resveratrol on some liver and blood parameters in methotrexate (MTX) induced toxicity in rats, Tunali-Akbay et al. [45] administered resveratrol (10 mg/kg, orally) for 5 days a er a single dose of MTX. The results showed that MTX administration increased the hepatic enzymes, TNF-α, MDA, myeloperoxidase and tissue factor activities and collagen contents and decreased GSH, while all of these alterations were reversed by resveratrol.
Roy et al. [46] also examined the chemopreventive potential of resveratrol in rat hepatic injury model by CCl 4 . Resveratrol (100 mg/kg, or 200 mg/kg body weight) was given orally for 8 weeks. They reported that resveratrol decreased the immunopositivity of TNF-α and IL-6 and restored the altered architectural structure of challenged hepatic tissue. Resveratrol also protected hepatic cells by suppressing oxidative stress and apoptosis.
Vitaglione et al. [47] investigated the eff ect of resveratrol on an animal model of CCl 4 -induced liver lipid peroxidation. Grape-stalk extract determining a daily resveratrol dosage of 3 mg/kg was given to the rats for 14 days. Resveratrol could reduce liver concentration of MDA a er 24 h and 1-week by 38% and a 63%, respectively.
Hepatic toxicity
Afl atoxin B1 is a potent hepatotoxic and hepatocarcinogenic mycotoxin. Lipid peroxidation and oxidative DNA damage are the principal manifestations of afatoxin B1-induced toxicity that could be counteracted by antioxidants. El-Agamy [48] compared the eff ect of curcumin (polyphenolic antioxidant purifed from turmeric) and resveratrol for possible protection against liver injury induced by afatoxin B1 in rats. Results showed that curcumin showed a signifi cant hepatoprotective activity by lowering the levels of serum marker enzymes, lipid peroxidation and elevating the levels of GSH, SOD, CAT, and GSH-Px. However, resveratrol failed to protect from the afatoxin B1-induced liver injury. Resveratrol (10 mg/kg) for 15 days in streptozotocin (STZ)-induced diabetic rats has shown hepatoprotective eff ects against diabetes-induced liver damage via reduction of serum glucose level and oxidative damage and improving serum lipid profi le. [49] Hepatic cholestatic injury Liver injuries can trigger a cascade of inflammatory responses and as a result, initiate the process of hepatic regeneration and fi brogenesis. To study the potential protective effects and mechanism of resveratrol on cholestatic liver injury, resveratrol was given (4 mg/kg/day) for either 3 days or 7 days a er bile duct ligation (BDL) injury. Resveratrol significantly reduced serum ALT, aspartate aminotransferase (AST) but not bilirubin on day 3. At this early stage of injury, resveratrol signifi cantly reduced TNF-α and IL-6 mRNA and decreased the number of Kupff er cells (CD681) recruited in the injured liver. It also decreased hepatic fibrosis. Totally resveratrol attenuated inflammation and reduced Kupffer cells activation leading to decrease in fi brosis and promotion of hepatocyte regeneration, which increased the survival of BDL mice. [50] Irradiation-induced hepatic injury Velioğlu-Öğünç et al. [51] studied the eff ects of resveratrol on ionizing radiation-induced oxidative injury. A er 10 days pretreatment with resveratrol (10 mg/kg), rats were exposed to whole-body IR (800 cGy) and the resveratrol treatment was continued for 10 more days after the irradiation. Resveratrol caused a signifi cant increase in GSH level, while MDA levels, myeloperoxidase activity and collagen content decreased in hepatic tissues. Similarly, plasma lactate dehydrogenase and pro-inflammatory cytokine levels, 8-hydroxy-2′-deoxyguanosine and leukocyte apoptosis decreased, while antioxidant-capacity increased in the irradiated rats with resvratrol as compared with the control group. Resveratrol treatment reversed histopathological alterations induced by irradiation. [51] Hepatic injury a er trauma-hemorrhage Resveratrol administration after trauma-hemorrhage attenuated hepatic injury, likely through reduction of proinfl ammatory mediators. Resveratrol-mediated hepatic preservation seemed to progress via an estrogen receptor (ER) related pathway. [52] 
ALCOHOLIC LIVER INJURY
Bujanda et al. [53] investigated the effect of resveratrol on alcohol-induced mortality and liver lesions in mice. They compared the eff ect of consuming alcohol, alcohol and resveratrol, and resveratrol alone. Transaminase concentration was signifi cantly higher in the alcohol group than in the other groups. IL-1 levels were signifi cantly reduced in the alcohol plus resveratrol group compared with the alcohol group. Histologically, the liver lesions were more severe in the alcohol group, though no signifi cant diff erences between groups were observed. Mortality in the alcohol group was 78% in the 7 th week, versus 22% in the alcohol plus resveratrol group. The results of this article suggest that resveratrol reduces mortality and liver damage in mice consuming alcohol. Kasdallah-Grissa et al. [54] investigated whether resveratrol has a preventive eff ect on the main indicators of hepatic oxidative status as an expression of the cellular damage caused by free radicals, and on antioxidant defense mechanism during chronic ethanol treatment. They prescribed 5 g/kg resveratrol to Wistar rats for 6 weeks and observed that dietary supplementation with resveratrol during ethanol treatment inhibited hepatic lipid peroxidation and ameliorated SOD, GPx and CAT activities in the liver so that resveratrol could have a benefi cial eff ect on inhibiting the oxidative damage induced by chronic ethanol administration. Jinghui et al. [55] investigated the eff ect of resveratrol (25, 50, or 100 mg/kg) on alcohol-induced hepatic injury and reported significant reduction in the concentrations of serum TNF-α, IL-6, ICAM-1 and the contents of liver NFκB p65, phosphorylating IκB-α compared with the model group consumed resveratrol for 7 days.
Hepatic oxidative damage
The eff ects of resveratrol on oxidative damage was examine by analyzing it's eff ects on sirtuins (SIRTs). SIRTs are NAD + -dependent deacetylases that catalyze the hydrolysis of acetyl-lysine residues. They play an important role in many physiological and pathophysiological processes, such as the regulation of lifespan and the prevention of metabolic diseases. Schirmer et al. [56] in their study analyzed the eff ect of resveratrol on the gene expression levels of SIRT1, SIRT3, SIRT4, PGC1a, and NAMPT, as well as its eff ect on NAD + and NADH levels, in the liver of nonstressed or nonimpaired wild-type zebra fi sh. They concluded that resveratrol plays a modulatory role in the transcription of the NAMPT, SIRT3, and SIRT4 genes. Schmatz et al. [12] investigated the eff ects of resveratrol on oxidative stress parameters in liver and serum biochemical parameters of STZ-induced diabetic rats. Animals were treated with 10 or 20 mg/kg resveratrol for 30 days. They reported the elevation in serum ALT, AST and γ-glutamiltransferase (GGT) activities as well as in levels of urea, creatinine, cholesterol, and TGs observed in the nonresveratrol group were reverted to levels close to normal by the administration of resveratrol. Reduction in TBARS and elevation in activities of CAT, SOD and aminolevulinic acid dehydratase, nonprotein thiols, and Vitamin C were also seen. Another study investigated the eff ect of resveratrol (0.1 or 1 mg/kg) on oxidative stress and infl ammatory response in the liver and spleen of STZinduced type 1 diabetic animal models. [57] The experimental results indicated that resveratrol signifi cantly decreased oxidative stress (superoxide anion content, protein carbonyl level and Mn-SOD expression) in both tissues and hepatic infl ammation (NF-κB and IL-1β), but implicated proinfl ammatory potential of resveratrol in diabetic spleen (TNF-α and IL-6). Lipopolysaccharide (LPS) is a glycolipid component of the cell wall of Gram-negative bacteria inducing deleterious eff ects on several organs including the liver. Sebai et al. [58] investigated the eff ect of pre-treatment with resveratrol on LPS-induced hepatotoxicity in rat. Resveratrol counteracted LPS-induced lipoperoxidation and depletion of antioxidant enzyme activities as SOD and CAT but slightly GPx activity. It also abrogated LPS-induced liver and plasma nitric oxide (NO) elevation and a enuated endotoxemia-induced hepatic tissue injury. Importantly resveratrol treatment abolished LPS-induced iron sequestration from plasma to liver compartment. In another study, 1 mg/kg/day resveratrol accompanied by standard diet and HFD in Wistar rats for 30 days; [59] in HFD, resveratrol improved lipid profi le and glucose level, enhanced SOD, and reduced oxidized low-density lipoprotein (ox-LDL) and hepatic oxidative stress. While in standard-fed-rats it reduced GSH-antioxidant defense system and enhanced hepatic lipid hydroperoxide. It may be concluded that resveratrol may have benefi cial eff ects in high-fat diets (e.g., ox-LDL, decreased serum and hepatic oxidative stress), but not in standard-fed diets (effects produced include enhanced hepatic oxidative stress). Bagul et al. [60] compared the eff ect of metformin (300 mg/kg) and resveratrol (10 mg/kg) on hepatic oxidative stress in fructose-fed rats. Administration of metformin or resveratrol normalized all the altered metabolic parameters. However, a marked insulin sensitizing action was only observed in the resveratrol group. Similarly, metformin administration failed to normalize the increased TBARS levels and decreased SOD activity, while resveratrol showed a more promising eff ect of all oxidative stress parameters measured in this study. This study demonstrates that resveratrol is more eff ective than metformin in improving insulin sensitivity, and a enuating metabolic syndrome and hepatic oxidative stress in fructose-fed rats. To investigate the hepatoprotective nature of resveratrol in averting hyperglycemia-mediated oxidative stress in the hepatic tissues of STZ-nicotinamide-induced diabetic rats, 5 mg/kg resveratrol was administered for 30 days. [61] In this study, resveratrol could decline hepatic proinfl ammatory cytokines and hepatic lipid peroxides, hydroperoxides and protein carbonyls. In addition, diminished activities of hepatic enzymic antioxidants as well as the decreased levels of hepatic nonenzymic antioxidants of diabetic rats were reverted to near normal by resveratrol administration. Moreover, the histological and ultrastructural observations evidenced that resveratrol eff ectively rescues the hepatocytes from hyperglycemiamediated oxidative damage without affecting its cellular function and structural integrity. Pyrogallol, an anti-psoriatic agent, causes hepatotoxicity in experimental animals. Resveratrol has hepatoprotective properties against pyrogallol. [62] In an animal study, administration of 10 mg/kg resveratrol modulated pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Reduction in ALT, AST, and lipid peroxidation were also seen. Farghali et al. [63] investigated the eff ects of resveratrol pretreatment on the enhancing action of D-galactosamine (D-GalN; 800 mg/kg) on (LPS; 0.5 l g/kg) inducing liver failure in rats. Reduction in ALT, AST, α-GST, TBARS, conjugated dienes and increase in CAT was seen according to resveratrol consumption. Kirimlioglu et al. [83] compared the antioxidant eff ects of resveratrol (30 mg/kg) and melatonin (10/kg) a er 70% partial hepatectomy (PH). Resveratrol and melatonin suppressed PH-induced oxidative damage, attenuated proliferation, and stimulated apoptosis. When resveratrol and melatonin were compared, resveratrol showed more potent antioxidative effects and was morphologically more protective to hepatocytes. Antiproliferative eff ects of melatonin were more potent. [64, 83] 1,2-dimethylhydrazine induced oxidative stress was suppressed by administration of resveratrol (20 mg/kg) for 30 weeks. [65] Resveratrol supplementation a enuated the liver lipid peroxidation with concomitant up-regulation of enzymic and nonenzymic antioxidant reserves.
Hepatic heat stress
The eff ects of dietary resveratrol on the induction of Hsp, transcription factors and antioxidative enzyme system in liver of quails under heat stress were investigated by Sahin et al. [66] They reported a linear increase in food intake, egg production, hepatic SOD, CAT, and GSH-Px activities as well as Nrf2 expression, but linear decrease in hepatic MDA concentrations and Hsp 70, Hsp90, and NF-кB expressions with increasing supplemental resveratrol level.
Hepatic steatosis
Xin et al. concluded that Alleviative eff ects of resveratrol on nonalcoholic fa y liver disease (NAFLD) are associated with up regulation of hepatic LDL receptor and scavenger receptor class B type I gene expressions. [67] Unexpectedly, increase in hepatic FASgene expressions was seen. [67] The eff ect of long-term administration (4 months) of resveratrol with high fructose (HF) diet (63%) on selected biochemical parameters and lipids content in diff erent tissues of rats was evaluated by Kopec et al. [68] The concentration of lipids was signifi cantly lower in the liver of animals fed with HFD by addition of 0.04% or 0.06% resveratrol. The concentration of TBARS (MDA equivalents) was signifi cantly lower (P < 0.05) in serum of rats fed HFD with the addition of 0.04% and 0.06% of resveratrol as compared to the rodents fed with negative fructose control diet and HFD. [68] Poulsen et al. [69] showed that an increased number of mitochondria and, particularly, an increase in hepatic uncoupling protein 2 expression might be involved in normalizing the hepatic fat content due to resveratrol supplementation in rodents fed a high-fat diet. To analyze the infl uence of resveratrol on hepatic TG metabolism, 30 mg/kg resveratrol was given to Sprague-Dawley rats for 6 weeks; resveratrol decreased liver fat accumulation, increased carnitine palmitoyl transferase-Iα and acyl-coenzyme A oxydase, and decreased ACC activities. [70] Male C57BL/6J mice were fed a normal diet or a HFD (20% fat, w/w) combined with 0.005 or 0.02 % (w/w) resveratrol for 10 weeks. [71] Resveratrol significantly reduced TAG and cholesterol, as well as lipid droplet number and size. A low dose of resveratrol (0.005%) appeared to be more eff ective than a higher dose of resveratrol (0.02 %) for suppressing adiposity and hepatic steatosis development with a signifi cant decrease in body weight gain, plasma TAG and total cholesterol levels. These changes were seemingly attributable to a suppression of the fatty acid (FA) synthase, glucose-6-phosphate dehydrogenase, and phosphatidate phosphohydrolase and/ or an activation of FA oxidation in the liver and epididymal adipose tissue. [71] Bujanda et al. [72] investigated whether resveratrol decreases hepatic steatosis in an animal model of steatosis and found that Fat deposition was decreased in the resveratrol group as compared to the control group. TNF-α and MDA levels were signifi cantly more increased in the control group. This was accompanied by increased SOD, GPx and CAT and decreased NOS in the liver of resveratrol group signifi cantly. Glucose levels were also decreased in the group of rats given resveratrol. Resveratrol treatment led to reduced lipid synthesis and increased rates of fa y acid oxidation and prevented alcoholic liver steatosis. The protective action of resveratrol is in whole or in part mediated through the upregulation of a SIRT1-AMPK signaling system in the liver of ethanol-fed mice. [73] Rats fed a high-fat diet developed abdominal obesity, NAFLD, and insulin resistance (IR), which were markedly improved by 10 weeks of resveratrol administration. Resveratrol treatment prevented the development of abdominal obesity and IR. Chronic resveratrol administration stimulated AMPK phosphorylation and downregulated SREBP-1c and FAS gene expressions in HFD rats. [15] Resveratrol (0.04%) for 20 weeks in senescence-accelerated mouse P10 hepatocytes caused the following results; [74] lipid droplets were reduced and mitochondria were increased in number in hepatocytes. Phosphorylation of acetyl-CoA carboxylase and the expression of both the mitochondrial ATP synthase β subunit and Mn SOD2 were increased. Mitochondria, expressing more SOD2, were more tightly associated with lipid droplets, suggesting the enhancement of lipolysis through the activation of mitochondrial functions. Cathepsin D expression was less in hepatocytes but enhanced in Kupff er cells, which were increased in number and size with more numerous lysosome-related profi les. [74] The antioxidant activity of resveratrol in cholesterol-fed rats, along with its hypolipidemic eff ects was determined by Zhu et al. [75] Resveratrol signifi cantly lowered serum lipid, hepatic cholesterol (TC), and TG levels compared to the control. Excretion of bile acids was signifi cantly enhanced by resveratrol. The overall potential of the antioxidant system was signifi cantly enhanced by the resveratrol as plasma and hepatic TBARS levels were lowered while serum SOD, GPx, and CAT activities were increased in nonresveratrol group. These fi ndings suggest that resveratrol maintains an antioxidant effi cacy as well as its anti-hyperlipidemic eff ect. Resveratrol (200 mg/kg/day) reduced body weight and liver weight gains, improved serum lipid parameters, reduced hepatic cholesterol accumulation and increased the bile acid pool size in mice fed an HFD for 8 weeks. [76] By feeding 10 or 50 ppm resveratrol in the diet to hepatomabearing rats for 20 days, solid tumor growth and metastasis tended to be suppressed dose-dependently. [77] Resveratrol (50 ppm) signifi cantly suppressed the serum lipid peroxide level, indicating its antioxidative properties or those of its metabolite (s) in vivo. Resveratrol dose-dependently suppressed both the serum TG and very low-density lipoprotein + LDL-cholesterol levels. [77] Liver fi brosis Oxidative stress in liver injury is a major pathogenetic factor in progress of liver fi brosis.
Resveratrol (10 and 20 mg/kg/day) or its vehicle was administered to cirrhotic rats for 2 weeks and results were as follow: [78] Reduction in portal pressure compared to vehicle without signifi cant changes in systemic hemodynamics. Reduction in portal pressure was associated with an improved vasodilatory response to acetylcholine, with decreased TXA2 production, increased endothelial NO, and with a signifi cant reduction in liver fi brosis. The decrease in hepatic fi brosis was associated with a reduced collagen-1, TGF-β, NFjB mRNA expression and desmin and α-SMA protein expression.
Hong et al. [79] investigated the protective effects of Resveratrol on dimethylnitrosamine (DMN)-induced liver fibrosis in rats and observed that resveratrol remarkably recovered body and liver weight loss due to DMN induced liver fi brosis. Liver histology showed that Resveratrol alleviated the infiltration of inflammatory cells and fi brosis of hepatic tissue. Resveratrol decreased the level of MDA and increased the levels of GPx and SOD. Also, It signifi cantly inhibited the mRNA expression of inflammatory mediators including inducible NO, TNF-alpha and IL-1beta. In addition, Resveratrol showed not only a reduction in mRNA expression of fi brosis-related genes such as transforming growth factor beta 1, collagen type I, and alpha-smooth muscle actin, but also a signifi cant decrease of hydroxyproline in rats with DMN-induced liver fi brosis.
Another study [80] has shown that resveratrol (20 mg/ kg daily for 4 weeks) remarkably prevented the DMNinduced loss in body and liver weight, and inhibited the elevation of serum alanine transaminase, aspartate transaminase, alkaline phosphatase, and bilirubin levels. Resveratrol also increased serum albumin and hepatic GSH levels and reduced the hepatic level of MDA due to its antioxidant effect. Furthermore, DMN-induced elevation of hydroxyprolinecontent was reduced in the Resveratrol treated rats, the result of which was consistent with the reduction in type I collagen mRNA expression. The reduction in hepatic stellate cell activation, as assessed by α-smooth muscle actin staining, and the reduction in transforming growth factor-β1 mRNA expression were associated with resveratrol treatment indicating the in vivo hepatoprotective and antifi brogenic eff ects of resveratrol against DMN-induced liver injury.
Lv et al. [81] assessed the eff ects of resveratrol (25, 50 , or 100 mg/kg, for 6 weeks) on chronic liver fi brosis induced by CCl 4 in rats. Rats fed with 50 and 100 mg/kg of resveratrol had significant reductions in levels of the serum ALT, and liver hydroxyproline and MDA and relieving liver fi brogensis, compared with the control group.
CONCLUSION
Resveratrol can play a pivotal role in prevention and treatment of liver disorders. Previous studies confi rmed its antioxidative properties in diff erent models of hepatitis resulting in reducing of hepatic fibrosis; on the other hand, Resveratrol could reduce hepatic steatosis through modulating the insulin resistance and lipid profile in animals. These high quality preclinical studies propose the potential therapeutic implication of Resveratrol in liver disorders especially those with hepatic steatosis. Additional carefully designed, mechanistic based, laboratory, and clinical studies need to be undertaken to provide scientifi c evidence for the effi cacy of it in treatment of liver disorders especially those with hepatic steatosis and fi brosis.
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